This course includes closed-captioning for your convenience.
Instructions for Credit — There is no fee for this activity. To receive credit for this CME/CE/CPE activity, participants must enroll in this course, review the accreditation and disclosure information, view the presentation in its entirety, successfully complete the post-activity assessment and evaluation/application for credit. If you do not achieve a minimum score of 70% on the post-activity assessment, you will be allowed to take it again. This course is accredited for up to 1.0 continuing education credits. Please retain a copy of the certificate for your records. For questions regarding the accreditation of this activity, please contact Medical Learning Institute, Inc. at (609) 333-1693 or firstname.lastname@example.org.
You must be enrolled to complete this activity for credit, however, you are not required to enroll simply to view the presentation.
To view the presentation, click on the presentation link at the bottom of the page.
Target Audience — Hematologists-oncologists, oncologists, physician assistant, nurse practitioners, oncology nurses, pharmacists and oncology social workers at the intermediate and advanced levels involved in the care of patients with hematologic malignancies.
Goal – This webinar will provide an overview of CAR T-cell Therapy for adult and pediatric patients, including a focus on diffuse large B-cell lymphoma as a treatment example.
|Learning Objectives — At the conclusion of this program, participants will be able to:|
|•||Describe the latest developments in CAR T-cell therapy options for adults and pediatric patients|
|•||Explain short and long-term side-effect management, including CRS and neurotoxicities|
|•||Discuss practical information in considering and treating a patient in a CAR T trial|
|•||Be more prepared to identify resources for professionals as well as for their patients|
Providers — This activity is jointly provided by The Leukemia & Lymphoma Society and Medical Learning Institute, Inc.
Supporter — This activity is supported by an educational grant from Kite, a Gilead Company.
Continuing Education for Physicians, Pharmacists, Nurses Practitioners, Nurses, and Social Workers
Physician Credit Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians. The Medical Learning Institute, Inc. designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Completion of this (knowledge-based activity provides for 1.0 contact hour (0.1 CEU) of continuing pharmacy education credit. The Universal Activity Number for this activity is 0468-9999-18-014-H01-P.
Nurse Practitioners Credit Designation
This activity is approved for 1.0 contact hour(s) of continuing education (which includes 1.0 hour pharmacology) by the American Association of Nurse Practitioners. Activity ID# 19023574. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.0 continuing education contact hour through the California Board of Registered Nursing.
Social Work Designation
The Leukemia & Lymphoma Society (LLS), Provider Number 1105, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org. Approved Continuing Education Program (ACE). Approval period: 12/10/2017 – 12/14/2020. LLS maintains responsibility for the program. Social workers should contact their regulatory board to determine course approval. Social workers will receive 1.0 CE clinical contact hour.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0117. LLS maintains responsibility for this program. Social workers will receive 1.0 CE clinical contact hour for this activity
Disclosure of Conflicts of Interest
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speaker’s bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc. and The Leukemia & Lymphoma Society, the accredited providers for this activity, do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME/CE/CPE activity during the past 12 months.
Julio C. Chavez, MD, MS, has disclosed he is a Consultant for Genentech, Kite, a Gilead Company, and Novartis Pharmaceuticals. He does not intend to reference unlabeled/unapproved uses of drugs or products in his presentation.
Rachel Lundberg, PA-C, has nothing to disclose. She does not intend to reference unlabeled/unapproved uses of drugs or products in his presentation.
Patricia Ensor, RPh, Content Expert Reviewer, has nothing to disclose.
Teresa Haile, RPh, MBA, Lead Pharmacy Planner, has nothing to disclose.
Siyang Leng, MD, Content Expert Reviewer, has nothing to disclose.
Leslie Smith, RN, AOCNS, APRN-CNS, Content Expert Reviewer, has nothing to disclose.
Disclaimer — The information provided in this CME/CE/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
|Estimated time to complete activity: 1.0 hours|
|Date of initial release: March 12, 2019|
|Valid for CME credit through : March 12, 2020|
Julio C. Chavez, MD, MS
Department of Malignant Hematology
Moffitt Cancer Center
Julio C. Chavez, MD, MS is a Medical Oncologist in the Lymphoma Section of the Department of Malignant Hematology at H. Lee Moffitt Cancer Center and Assistant Professor in the Department of Oncologic Sciences at the University of South Florida. He also holds a Master’s Degree in Clinical Research at the University of South Florida. He received his clinical training in Internal Medicine at the State University of New York at Buffalo, New York and completed his Medical Oncology fellowship at the University of South Florida/Moffitt Cancer Center in Tampa, Florida.
Dr. Chavez is board-certified in Internal Medicine and Medical Oncology. His focus of clinical and research interest are on lymphoid malignancies, specifically aggressive B-cell lymphomas, virally-related lymphoid malignancies and chronic lymphocytic leukemia. He is currently principal investigator and co-investigator in several cellular based immunotherapies, including chimeric antigen receptor therapy (CART) in lymphoid malignancies and leukemia.
Rachel Lundberg, PA-C
Moffitt Cancer Center
Rachel Lundberg, PA-C, earned her Masters of Physician Assistant Studies at the University of Wisconsin-Madison, in Madison, Wisconsin. She is a Physician Assistant in the Blood and Marrow Transplant and Cellular Immunotherapy Program at the Moffitt Cancer Center in Tampa, Florida. In this role, she is the primary clinic provider in the Cellular Therapy Clinic, where she evaluates patients for chimeric antigen receptor T-cell therapy and other immunologic therapies.
Ms. Lundberg also served as a Physician Assistant at Froedtert Hospital and the Medical College of Wisconsin in Milwaukee, Wisconsin, where she managed the acute medical issues of patients with hematologic malignancies or solid tumors and patients undergoing bone marrow transplant. She has also served as Adjunct Professor at Concordia University in Milwaukee, Wisconsin and has guest lectured at the University of South Florida teaching courses in hematology/oncology and emergency medicine.
Free Healthcare Professional Resources
Online & In-person free CME & CE courses: www.LLS.org/CE
Clinical Trials and Research
- Clinical Trials: Learn more about clinical trials: LLS.org/ClinicalTrials
- Research: Focused on finding cures, driving research in areas of unmet medical need, and bridging the gap between academic discovery & drug development: LLS.org/Research
Advocacy dedicated to removing barriers to care: www.LLS.org/Advocacy
Free Patient and Caregiver Resources
CART specific resources: www.LLS.org/CART
Free Information Booklets: www.LLS.org/Booklets
Support Resources : www.LLS.org/Support
- Financial Assistance
- Travel Assistance
- Referral to Medication Access programs
- Information Resource Center
- LLS Chapters
- LLS Community (social media platform)
- Patti Robinson Kaufman First Connection Program (peer-to-peer)
- One-On-One Nutrition Consultations (PearlPoint)
Additional support resources: www.LLS.org/support
Information Resource Specialists: www.LLS.org/IRCAssist through treatment, financial & social challenges, and give accurate treatment and support information. HCPs can also order free materials to distribute to patients.
Clinical Trial Support Center: www.LLS.org/CTSCPatients & caregivers work one-on-one with clinical trial specialists who are registered nurses with expertise in blood cancers. RNs will personally assist through the clinical trial process, providing an additional resource to your HCP team.